Brought to you by

InterMune sells Infergen to Valeant
09 Aug 2006
Executive Summary
InterMune has sold Valeant Pharmaceuticals its US and Canadian rights to the hepatitis C treatment Infergen (interferon alfacon-1).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com